Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome

Objective To compare the efficacy of statins and ɑ blockers drug therapies for benign prostatic hyperplasia (BPH) in patients with metabolic syndrome (MetS). Materials and method A total of three hundred patients were randomly distributed into three groups of one hundred patients each. Group 1 received only ɑ-adrenoceptor antagonist (ɑ-blocker, AB) (Tamsulosin), group 2 received only statin (atorvastatin), and group 3 received AB plus statin (Tamsulosin + Atorvastatin). The efficacy measurement was assessed by analyzing the changes from baseline in the total International Prostate Symptom Score (IPSS), disease-specific QoL question score and maximum urinary flow rate at the end of 6 months in each group and between the three groups. Results Pre-treatment and post-treatment value of triglycerides (TG), high-density lipoprotein (HDL), and prostate volume (PV) were not significantly different in AB group, while TG and PV were significantly lower in patients taking statin and combined therapy. The significant decrease was demonstrated in maximum urinary flow rate (Qmax) in three groups. However, the most significant decrease was observed in the combination therapy group. IPSS, postvoid residual urine volume (PVR), and Quality of Life score (QoL) significantly changed in three groups. Conclusion We recommend of the use of statins in those men with BPH accompanied by MetS in which AB is ineffective alone.